1. Background {#sec0005}
=============

A number of multipathogen molecular platforms for the simultaneous detection of a wide array of pathogens are being developed to rapidly determine the cause of respiratory disease outbreaks of unknown etiology, and to facilitate surveillance for expanded etiologies of acute respiratory infection (ARI).[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040] One such system, the TaqMan^®^ Array Card (TAC), (Life Technologies™, Carlsbad CA), allows simultaneous, singleplex, reverse transcription real-time PCR (RT-qPCR) to be performed in a 384-well microfluidic card format. This card-based system has been used successfully to study brain endothelial cell gene expression, miRNA expression profiling, and biologic agent detection.[@bib0045], [@bib0050], [@bib0055], [@bib0060] Flexible card formatting allows simultaneous testing of 6--7 clinical specimens for the presence of 21 or more targeted pathogens along with appropriate positive and negative assay controls.

Kodani et al.,[@bib0010] reported the first application of TAC (formerly TLDA, TaqMan^®^ Low Density Array) for infectious diseases diagnostics using a card designed for simultaneous detection of 21 different respiratory viral and bacterial pathogens. Advantages of the TAC system included simple and easy operation; reproducible and simultaneous analyses of multiple pathogens using small sample volumes; a level of detection generally within one ten-fold dilution of individual RT-qPCR assays; a lower risk of amplicon contamination as the system is entirely closed; and unlike other multiplex platforms, the ability to modify or replace individual pathogen assay primer/probes without requiring the re-optimization and validation of the entire panel.[@bib0010] However, several gaps in knowledge remained after completion of that study.[@bib0010] First, the frozen, archived clinical specimens utilized were collected from various studies and locations over a 10 year period, preventing evaluation of standardized methods or establishing epidemiologic associations. Second, the total nucleic acid (TNA) extracts were diluted in order to provide sufficient volume to perform comparisons of TAC with individual RT-qPCR assays; this factor, along with the frozen storage, may have contributed to the decreased sensitivity of the TAC assay relative to the individual RT-qPCR assays. Third, in order to achieve a consensus in the amplification conditions for all deployed individual RT-qPCR and TAC assays, a higher probe-annealing temperature of 60 °C was chosen as required for optimal bacterial assay specificity, but with the potential loss in sensitivity of some viral assays designed to run at 55 °C. Loss of viral sensitivity might have biased the results toward increased concordance among falsely negative individual RT-qPCR assays and TAC assays, resulting in an overestimate of TAC sensitivity for viruses.

2. Objectives {#sec0010}
=============

We wished to extend the work of Kodani et al.,[@bib0010] by applying TAC to a larger field study of systematically collected specimens from children with well-characterized recent fever or acute respiratory infection (ARI). We used specimens from 942 children enrolled in the New Vaccine Surveillance Network (NVSN), which has conducted systematic, population-based surveillance for ARI under standardized protocols for the collection of epidemiologic and microbiologic data.[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090] The sensitivity and specificity of viral detection by the TAC assay format was determined for 10 target respiratory viruses for which we had standard individual RT-qPCR assays in place, using the identical primer and probe sets for TAC and individual RT-qPCR ([Table 1](#tbl0005){ref-type="table"} ).[@bib0065], [@bib0090], [@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115] The individual RT-qPCR assays were optimized for viral detection, using an annealing temperature of 55 °C, to maximize the sensitivity of the "gold standard".Table 1Primers and probes used in this study for both individual RT-qPCR and TAC assays.AssayPrimer/probe sequence (5′--3′)[a](#tblfn0005){ref-type="table-fn"}Source or referenceAdenovirusF, GCC CCA GTG GTC TTA CAT GCA CAT C[@bib0010]R, GCC ACG GTG GGG TTT CTA AAC TTP, TGC ACC AGA CCC GGG CTC AGG TAC TCC GAHMPVF, CAA GTG TGA CAT TGC TGA YCT RAA[@bib0010]R, ACT GCC GCA CAA CAT TTA GRA AP, TGG CYG TYA GCT TCA GTC AAT TCA ACA GAHPIV-1[b](#tblfn0010){ref-type="table-fn"}F, AGT TGT CAA TGT CTT AAT TCG TAT CAA T[@bib0010]R, TCG GCA CCT AAG TAA TTT TGA GTTP, ATA GGC CAA AGA "T"TG TTG TCG AGA CTA TTC CAAHPIV-2F, GCA TTT CCA ATC TAC AGG ACT ATG A[@bib0010]R, ACC TCC TGG TAT AGC AGT GAC TGA ACP, CCA TTT ACC "T"AA GTG ATG GAA TCA ATC GCA AAHPIV-3F, TGG YTC AAT CTC AAC AAC AAG ATT TAA G[@bib0010]R, TAC CCG AGA AAT ATT ATT TTG CCP, CCC RTC TG"T" TGG ACC AGG GAT ATA CTA CAA AHPIV-4F, CTG CCA AAT CGG CAA TTA AAC[@bib0100]R, CTG GCA GCA ATC ATA AGR TGA TTCP, CA TTA TTA TCT CTG C"T"T TCC TTA CAG GCC ACA TCAInfluenza AF, GAC CRA TCC TGT CAC CTC TGA C[@bib0010], [@bib0115]R, AGG GCA TTY TGG ACA AAK CGT CTAP, TGC AGT CCT CGC TCA CTG GGC ACGInfluenza BF, TCC TCA ACT CAC TCT TCG AGC G[@bib0010], [@bib0110]R, CGG TGC TCT TGA CCA AAT TGGP, CCA ATT CGA GCA GCT GAA ACT GCG GTGRhinovirus[c](#tblfn0015){ref-type="table-fn"}F1, C(P)\[A\] GCC \[T\]GC GTG GC[@bib0010], [@bib0135]F2, C(P)\[A\] GCC \[T\]GC GTG GTR, GAA ACA CGG ACA CCC AAA GTAP, TCC TCC GGC CCC TGA ATG YGG CRSVF, GGC AAA TAT GGA AAC ATA CGT GAA[@bib0010]R, TCT TTT TCT AGG ACA TTG TAY TGA ACA GP, CTG TGT ATG TGG AGC CTT CGT GAA GCTRNP3 controlF, CCA AGT GTG AGG GCT GAA AAGThis workR, TGT TGT GGC TGA TGA ACT ATA AAA GGP, CC CCA GTC TCT GTC AGC ACT CCC TTC[^2][^3][^4]

3. Study design {#sec0015}
===============

3.1. Overall study design {#sec0020}
-------------------------

### 3.1.1. Population-based surveillance and study cohort {#sec0025}

The NVSN conducted surveillance for ARI among children during 2000--2009 in 3 US counties that include the cities of Rochester, New York, Nashville, Tennessee, and Cincinnati, Ohio. The overall surveillance design and laboratory methodology have been described previously.[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095] Since the distribution of viruses has been relatively similar across the 3 counties and resources were limited, we utilized only specimens from the Rochester (Monroe County) New York NVSN site for the study cohort. TAC and individual RT-qPCR assay results were compared for in the cohort, which was comprised of 942 children with fever or acute respiratory infection: 281 hospitalized children \<5 years of age enrolled from October, 2008 through September, 2009, and 661 children \<13 years of age seen in the Emergency Department or Ambulatory Clinic enrolled from October, 2008 through June, 2009.

### 3.1.2. Specimen and data collection {#sec0030}

As part of standard NVSN protocols, informed consent from parents/guardians, detailed epidemiologic data from parent interviews, provider immunization data, and both mid-turbinate nasal and throat swab specimens (sterile non-flocked polyester-tipped applicators, Puritan Medical, Guilford, ME) were collected from all enrolled children. The swabs were combined in Universal Transport Medium (Diagnostic Hybrids, Athens, OH), refrigerated and added to lysis buffer (Qiagen Lysis Buffer AVL, QIAGEN Inc., Valencia, CA) within 24 h; aliquots of original sample and sample in lysis buffer were stored at −80 °C. The lysis buffer served to prevent viral particle degradation during sample freezing, to inactivate RNases present in samples, and to stabilize intact viral RNA for future analysis.

3.2. Molecular virology {#sec0035}
-----------------------

All laboratory testing for this work was performed at the University of Rochester Medical Center.

### 3.2.1. Total nucleic acid extraction (TNA) {#sec0040}

TNA was extracted from 140 μL of each specimen aliquot in lysis buffer, to a final eluate volume of 100 μL, using the QIAamp Viral RNA Mini Kit (QIAGEN) on a QIAcube robot (QIAGEN). To minimize freeze-thawing, three TNA aliquots for each extracted clinical specimen were prepared and stored at −80 °C until use.

### 3.2.2. Individual RT-qPCR assays {#sec0045}

Individual RT-qPCR assays for 10 viruses (adenovirus, human metapneumovirus \[HMPV\], human parainfluenza viruses 1--4 \[HPIV-1-4\], influenza viruses A and B, respiratory syncytial virus \[RSV\], and rhinovirus) and the human RNase P (RNP) reference gene control were used for comparison with TAC ([Table 1](#tbl0005){ref-type="table"}). All individual RT-qPCR assays, except those for HPIV-4 and influenza viruses A and B, were performed on an Applied Biosystems^®^ 7500 Real-Time PCR system (Life Technologies™), using the AgPath-ID™ One-Step RT-PCR (Life Technologies™) kit previously described by Kodani et al.,[@bib0010] but modified to use standard optimal thermocycling conditions for viral assays: 45 °C for 10 min, 95 °C for 10 min, and 45 cycles of 95 °C for 15 s and 55 °C for 45 s. The individual RT-qPCR for HPIV4 was performed on a Bio-Rad MyiQ™ RT-qPCR thermal cycler (Bio-Rad Laboratories, Hercules, CA), using the conditions noted above. Influenza viruses A and B assays were performed on the Bio-Rad MyiQ™ RT-qPCR thermal cycler, using SuperScript^®^ III Platinum^®^ One-Step RT-PCR chemistry (Life Technologies™) with the following thermocycling conditions: 50 °C for 30 min, 95 °C for 2 min, and 45 cycles of 95 °C for 15 s and 55 °C for 30 s.[@bib0115] Cycle threshold (C~*T*~) values were assigned to specimens exhibiting exponential fluorescence curves and acceptable control results (i.e., negative results for no-template controls and positive results for RNP reference gene control). For this study, a C~*T*~ value of ≤40 was considered a positive test result.

### 3.2.3. TAC assay {#sec0050}

The panel of TAC assays used in this study was modified from Kodani et al.,[@bib0010] and included 16 viral and 7 bacterial respiratory pathogens (adenovirus, HMPV, HPIV 1-4, influenza viruses A, B, and C, RSV, rhinovirus, human coronaviruses 229E, NL63, OC43, HKU1, enterovirus, *Bordetella pertussis, Chlamydophila pneumoniae, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, Streptococcus pneumoniae*, and *S. pyogenes*). Because of resource limitations, individual RT-qPCR assays could be performed for only 10 viruses; TAC assay results presented herein therefore are limited to those for the 10 viral pathogens ([Table 1](#tbl0005){ref-type="table"}). The TAC cards were created and handled in the same fashion as in the Kodani et al. study,[@bib0010] with identical primers and probes used ([Table 1](#tbl0005){ref-type="table"}) except that in this work HPIV-4 was added to our new TAC cards and to our panel of individual RT-qPCR assays. In addition, the rhinovirus primers and probes were slightly modified for both our TAC and RT-qPCR ([Table 1](#tbl0005){ref-type="table"}). Our TAC cards also contained primers & probes for influenza C and 4 coronavirus types, but as noted, these are not relevant for the current report.

All synthetic oligonucleotide primer/probes used for individual RT-qPCR assays and TAC were designed by the Centers for Disease Control and Prevention (CDC) and synthesized by BioSearch Technologies Inc., Novato, CA. Primer/probes for the 10 selected virus assays were spotted in duplicate on each card by Life Tchnologies™; quality control assays were performed by both the company and CDC. All viral assays on the two lots of TAC cards used in this study were qualified for use by the using standard reference control reagents. In addition to the viral primers/probes, a proprietary internal positive control (IPC) assay was spotted in duplicate with its oligonucleotide template (Life Technologies™) to monitor for specimen inhibitors of RT-qPCR, and the RNP assay noted above was spotted singly to monitor specimen quality. An assay for human glyceraldehyde 3-phosphate dehydrogenase also was included on each card by the manufacturer for quality control of card production lots; results from this assay were not included in our analysis. Each card tested included 7 clinical specimens and 1 no-template negative control (reaction mix plus water) to monitor for assay contamination. Positive control pools (viral genome or synthetic templates) were periodically run at pre-specified intervals (including at the beginning, mid-point, and end of the study) on cards to monitor pathogen- and RNP-specific assay performance. All controls were monitored throughout the study to ensure test validity.

For each specimen tested, 20 μL of TNA extract and 80 μL of AgPath-ID™ One-Step RT-PCR master mix were loaded into one of the 8 TAC ports. The cards were centrifuged twice to distribute the TNA/master mix throughout the 48 inter-connected wells (per specimen) containing the pre-spotted primer/probes. Each card was then sealed and run on a ViiA™-7 Real-time PCR System (Life Technologies™) using the following thermocycling conditions: 45 °C for 10 min, 94 °C for 10 min, and 45 cycles of 94 °C for 30 s followed by 60 °C for 1 min as described by Kodani et al.[@bib0010] Assignment of C~*T*~ values and positive test results were as indicated above for individual RT-qPCR assays.

3.3. Statistical analyses {#sec0055}
-------------------------

C~*T*~ values are presented as the mean of two duplicate wells for specimens yielding positive assays. For specimens with discordant positive and negative duplicate well C~*T*~ values (\<8% of positive viral specimens by TAC), only the positive value was assigned. Sensitivity and specificity were calculated using the individual RT-qPCR results as the "gold standard". The 95% confidence intervals (95% CI) around the point estimates for sensitivity were calculated according to the efficient-scores method (corrected for continuity)[@bib0120], [@bib0125], [@bib0130] using the VassarStats: Website for Statistical Computation (<http://vassarstats.net/>). Grouped data are presented as means ± SD or as medians with range or interquartile range (IQR) as noted.

4. Results {#sec0060}
==========

4.1. TAC sensitivity {#sec0065}
--------------------

Of the 942 clinical specimens tested by individual RT-qPCR assays, 713 (76%) were positive for one or more of the 10 respiratory viruses evaluated; 109 (12%) specimens were positive for more than one virus for a total of 837 viruses detected. The comparative sensitivities of the TAC assay for each of the 10 individual target virus RT-qPCR assays are shown in [Table 2](#tbl0010){ref-type="table"} . The overall sensitivity for all viruses of TAC was 83%, with individual virus assay sensitivities ranging from 54 to 95%. The TAC assays for influenza A and B, HMPV, and RSV exhibited the highest sensitivities, ranging from 86% to 95%, whereas the assays for adenovirus and HPIV-1 had the lowest sensitivities (54% and 56%, respectively).Table 2Comparison of individual RT-qPCR and TAC assay results.VirusCharacteristicIndividual RT-qPCR AssayTAC assay% Sensitivity (95% CI)[a](#tblfn0020){ref-type="table-fn"}AdenovirusNo. positive814454 (43--65)Mean C~*T*~ ± SD30.74 ± 6.3130.60 ± 5.17Median C~*T*~ (Range)33.27 (15.03--38.27)31.10 (16.31--39.58)HMPVNo. positive736386 (76--93)Mean C~*T*~ ± SD28.03 ± 6.1129.34 ± 5.09Median C~*T*~ (Range)28.32 (13.04--39.44)29.03 (18.02--38.63)HPIV-1No. positive16956 (31--79)Mean C~*T*~ ± SD30.68 ± 4.8435.88 ± 3.74Median C~*T*~ (Range)30.00 (22.30--39.40)36.01 (29.63--40.00)HPIV-2No. positive4375 (22--99)Mean C~*T*~ ± SD32.14 ± 6.2433.31 ± 5.36Median C~*T*~ (Range)33.97 (23.15--37.48)36.10 (27.13--36.69)HPIV-3No. positive443682 (67--91)Mean C~*T*~ ± SD24.88 ± 7.3425.30 ± 4.50Median C~*T*~ (Range)24.07 (13.28--38.01)25.31 (18.24--34.82)HPIV-4No. positive121192 (60--99)Mean C~*T*~ ± SD32.57 ± 4.4430.74 ± 4.34Median C~*T*~ (Range)33.15 (24.93--39.47)32.04 (23.15--36.44)Influenza ANo. positive11510995 (89--98)Mean C~*T*~ ± SD29.62 ± 5.2227.77 ± 4.67Median C~*T*~ (Range)29.28 (18.40--39.62)27.63 (18.23--36.47)Influenza BNo. positive252392 (72--99)Mean C~*T*~ ± SD30.38 ± 5.5326.74 ± 4.43Median C~*T*~ (Range)29.61 (22.09--39.64)27.22 (20.05--34.19)RhinovirusNo. positive27121880 (75--84)Mean C~*T*~ ± SD28.58 ± 5.4030.23 ± 4.61Median C~*T*~ (Range)28.60 (12.72--39.69)30.81 (17.47--40.00)RSVNo. positive20118994 (90--97)Mean C~*T*~ ± SD23.65 ± 4.9424.78 ± 4.09Median C~*T*~ (Range)22.46 (14.75--39.36)24.09 (16.20--35.35)[^5]

In general, C~*T*~ values for TAC were similar to those of the individual RT-qPCR assays ([Table 2](#tbl0010){ref-type="table"}), and the linear concordance between the two systems was high ([Fig. 1](#fig0005){ref-type="fig"} ). TAC C~*T*~ values tended to be slightly higher than individual RT-qPCR values, as denoted in [Fig. 1](#fig0005){ref-type="fig"} by values above the reference line, except for influenza viruses A and B. When TAC results were most discordant with individual RT-qPCR assay results, it nearly always was at the higher range of the individual RT-qPCR C~*T*~ values (30--40 C~*T*~); TAC was almost always positive when the individual RT-qPCR C~*T*~ values were \<30, with the notable exception of the rhinovirus assay ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1TAC C~*T*~ values plotted against those of individual RT-qPCR assays by target virus. For better visualization of the results, all negative test results for either RT-qPCR or TAC were assigned a C~*T*~ value of 45. The dotted line represents the line of identity between the individual RT-qPCR and TAC results.

During the study it was noted that the HPIV-1 TAC performance lagged behind that of the other TAC assays. Thirteen samples positive for HPIV-1 by individual RT-qPCR were available for further testing, and retested by TAC with annealing temperatures of 55 °C. An improvement in TAC assay HPIV-1 performance was obtained at the lower annealing temperature, with assay sensitivity increasing from 69% (9/13) to 100% (13/13).

A comparison of the point estimates of sensitivity, as well as the number of true positive viruses tested (as defined by positive individual RT-qPCR results), from both the work of Kodani et al.[@bib0010] and the present work is presented in [Table 3](#tbl0015){ref-type="table"} (95% CI shown in [Table 3](#tbl0015){ref-type="table"} for the results of Kodani et al.[@bib0010] were recalculated by the same methods as those for the present results).Table 3Comparison of TAC sensitivity in this and previous work[a](#tblfn0025){ref-type="table-fn"}VirusCharacteristicTAC assay---This WorkTAC assay---Kodani et al[b](#tblfn0030){ref-type="table-fn"}AdenovirusNo. true positives8128% Sensitivity (95% CI)54 (43--65)97 (80--100)HMPVNo. true positives7319% Sensitivity (95% CI)86 (76--93)95 (73--100)HPIV-1No. true positives167% Sensitivity (95% CI)56 (31--79)[c](#tblfn0035){ref-type="table-fn"}100 (56--100)HPIV-2No. true positives411% Sensitivity (95% CI)75 (22--99)79 (49--94)HPIV-3No. true positives4421% Sensitivity (95% CI)82 (67--91)95 (75--100)HPIV-4No. true positives12Not tested% Sensitivity (95% CI)92 (60--99)Influenza ANo. true positives11522% Sensitivity (95% CI)95 (89--98)92 (72--99)Influenza BNo. true positives2514% Sensitivity (95% CI)92 (72--99)100 (73--100)RhinovirusNo. positives27141% Sensitivity (95% CI)80 (75--84)98 (86--100)RSVNo. true positives20130% Sensitivity (95% CI)94 (90--97)100 (86--100)[^6][^7][^8]

4.2. TAC specificity {#sec0070}
--------------------

There were 8 instances of apparent false positive TAC assay results (1 RSV and 7 rhinovirus positives) among samples negative by RT-qPCR, for an overall TAC specificity of 99%.

4.3. TAC precision and reproducibility {#sec0075}
--------------------------------------

Throughout the study, C~*T*~ values of the positive control pools were tightly distributed, with coefficients of variation (CV) ranging from 1.5 to 4.5% for each target virus and for the RNP gene control ([Table 4](#tbl0020){ref-type="table"} ). C~*T*~ values for the IPC were also tightly distributed (CV ≤3%), and had similar mean and median values whether respiratory specimen TNA extracts or water (no-template control) were present, indicating the absence of RT-qPCR inhibitors in the study specimens ([Table 4](#tbl0020){ref-type="table"}).Table 4Reproducibility of TAC assay controls throughout the study.C~*T*~ControlNo. testedMean ± SDMedian (IQR)CV (%)Virus positive control Adenovirus2430.08 ± 0.7130.21 (29.57--30.61)2.36 HMPV2430.33 ± 1.1429.96 (29.60--30.43)3.76 HPIV-12429.18 ± 0.5629.15 (28.25--29.44)1.92 HPIV-22430.16 ± 0.4730.10 (29.87--30.47)1.56 HPIV-32431.24 ± 0.9731.18 (30.72--31.54)3.10 HPIV-42430.56 ± 1.0030.57 (29.62--31.22)3.27 Influenza A826.57 ± 1.1726.24 (25.74--26.92)4.42 Influenza B831.67 ± 1.4429.97 (30.69--32.29)4.55 Rhinovirus2429.82 ± 1.1129.95 (29.15--30.26)3.72 RSV2429.89 ± 0.6929.87 (29.51--30.26)2.31 RNP reference gene control[a](#tblfn0040){ref-type="table-fn"}2429.09 ± 0.8829.06 (28.68--29.73)3.03Internal positive control Clinical specimens94225.19 ± 0.6725.28 (24.78--25.63)2.68 No-template control (water)51725.71 ± 0.7825.68 (25.20--26.22)3.03[^9]

5. Discussion {#sec0080}
=============

We found that the TAC assay offers a simple, sensitive, reproducible and moderate throughput system for simultaneous detection of multiple respiratory pathogens. TAC assays for all pathogens were accomplished with only 20 μL of nucleic acid extract and 80 μL of reaction mix per patient sample, with card setup and run times of \~3 h, excluding sample extraction; 3 cards (up to 21 samples) could be feasibly run on a single machine in a normal workday. In contrast, completing up to 21 individual RT-qPCR reactions for each clinical sample would require 125 μL of nucleic acid extract and 420 μL of reaction mix, as well as a much greater amount of technician time, precluding throughput of even 1 clinical specimen tested for all pathogens per day. Additional advantages of the TAC assay were a combined datafile output of all pathogens tested per specimen, such that merging of results of separate RT-qPCR assays was not required; and the avoidance of pipetting errors in the multi-well plate RT-qPCR assays by the automated setup of the TAC array assay. Indeed, excellent reproducibility of all controls was maintained throughout the duration of the study.

Among the 942 clinical specimens tested by both individual RT-qPCR and TAC assays for the 10 target viruses, the overall TAC sensitivity and specificity were 83% and 99%, respectively. Kodani et al.,[@bib0010] found TAC sensitivity and specificity to be 95% and 98% in a smaller test set of 192 virus-positive specimens for 9 of the same target viruses (HPIV-4 not included). Our analysis yielded similar estimates of sensitivity and specificity for each virus assay, except for lower sensitivity for adenovirus, rhinovirus, and HPIV-1 ([Table 3](#tbl0015){ref-type="table"}). Part of this discrepancy might be explained by the fact that Kodani et al.,[@bib0010] used an annealing temperature of 60 °C for their individual RT-qPCR assays, which may have decreased the RT-qPCR sensitivity, thus making it more concordant with any negative TAC assay results (i.e., more false negative RT-qPCR results would have increased the concordance with false negative TAC results, raising the estimates of TAC sensitivity for adenoviruses and rhinoviruses). An additional factor may be greater strain variation in adenoviruses and rhinoviruses, reducing the performance of the TAC primers/probes for those viruses when analyzed at 60 °C rather than at 55 °C. We were not able to pursue studies of the effects of adenovirus and rhinovirus strain variation and annealing temperature on the TAC assay due to limited resources.

We also noted decreased TAC assay sensitivity for HPIV-1. Since one of the advantages of the closed TAC system is the ability to modify or replace primer/probes for individual pathogens without requiring the re-optimization and validation of the entire panel,[@bib0010] we have updated the HPIV-1 primers for future TAC cards to improve assay sensitivity at 60 °C ([Table 1](#tbl0005){ref-type="table"}).

One major limitation of this study is that we did not perform individual RT-qPCR analyses for several of the viral and bacterial pathogens on the TAC array, and were therefore unable to study these assays in this work; however, Kodani et al. found good performance for detection of bacterial pathogens in their study.[@bib0010] Also, low numbers of positive clinical specimens for HPIV1, 2, and 4 and influenza B virus led to wide 95% confidence intervals around the point estimates for TAC sensitivity. However, it should be noted that the 95% confidence intervals around the estimates of viral sensitivity overlapped for our results and those of Kodani et al[@bib0010] for these and nearly all other viruses tested ([Table 3](#tbl0015){ref-type="table"}).

We were not able to compare the TAC performance directly with other array technologies such as the FilmArray^®^ Respiratory Panel (BioFire Diagnostics, Inc., Salt Lake City, UT) or the Luminex xTAG^®^ Respiratory Viral Panel (Luminex Corporation, Austin, TX). The daily throughput of patient samples may be several-fold greater with the TAC assay, but the instrumentation costs may be greater as well. As clinical laboratories move toward implementation of array technology, such inter-assay comparative data would be informative.

The major strength of this study was the use of a large collection of field specimens from a well-characterized group of children enrolled in the NVSN to more fully examine the clinical performance of the TAC assay in a more "real-world" clinical diagnostic laboratory setting, with the individual RT-qPCR optimized for maximum sensitivity of the "gold standard". The rich NVSN epidemiologic and clinical database, combined with TAC assay results, should permit an evaluation of the clinical relevance of co-detection of two or more pediatric respiratory pathogens,[@bib0005], [@bib0010], [@bib0015], [@bib0025], [@bib0030], [@bib0035], [@bib0105] including those not commonly studied (e.g., influenza C, HPIV-4, human coronaviruses). As new pathogens become recognized and RT-qPCR assays become available, they can be quickly and easily introduced into the TAC array, and used to investigate outbreaks of respiratory illness of unknown etiology.[@bib0105], [@bib0135], [@bib0140]
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[^1]: Deceased.

[^2]: F, forward primer; R, reverse primer; P, probe; (P) = dP-CE (pyrimidine derivative); \[A\] = LNA-dA, \[T\] = LNA-dT \[Locked Nucleic Acid (LNA) primers, Exiqon, Woburn, MA\]. TaqMan^®^ probes labeled at the 5′-end with the reporter molecule 6-carboxyfluorescein (FAM) and at the 3′-end with Black Hole Quencher^®^ 1 (BHQ1; Biosearch Technologies Inc., Novato, CA) with the exception of probes that are internally quenched with BHQ1 located at a modified "T" residue and a 3′ terminal Spacer 3 (Biosearch Technologies, Inc.) to prevent probe extension by Taq polymerase.

[^3]: Subsequent to this study, the HPIV-1 primers were redesigned to improve assay performance at 60 °C annealing temperature: F, ACA AGT TGT CAA YGT CTT AAT TCR TAT; R, TCG GCA CCT AAG TAR TTY TGA GTT.

[^4]: The rhinovirus RT-qPCR assay may cross-react with some enterovirus strains if present at high viral load.

[^5]: Sensitivity of TAC assay calculated assuming individual RT-qPCR test results as "gold standard".

[^6]: Sensitivity of TAC assay for each work calculated assuming individual RT-qPCRtest results as "gold standard".

[^7]: FromKodani et al.[@bib0010], with recalculated 95% CIs calculated by efficient-score method, corrected for continuity (see Methods).

[^8]: Rose to 100% (95% CI 76--100) when new primer/probe set used---see text.

[^9]: Virus positive control pools contained human nucleic acid for RNP control.
